Effect of ranolazine on rat intrarenal arteries in vitro

European Journal of Pharmacology

Volumn 683, Issue 1-3, 2012, Pages 211-216

  Deng, Chun Yu ^a   Kuang, Su Juan ^a   Rao, Fang ^a   Yang, Hui ^a   Fang, Xian Hong ^a   Shan, Zhi Xin ^a   Li, Xiao Hong ^a   Zhou, Zhi Ling ^a   Lin, Qiu Xiong ^a   Yang, Min ^a   Wu, Shu Lin ^a   Yu, Xi Yong ^a   Lin, Shu Guang ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM ION; ENDOTHELIN 1; NIFEDIPINE; NORADRENALIN; PRAZOSIN; RANOLAZINE; YOHIMBINE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL CELL; ANIMAL TISSUE; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTERY MUSCLE; ARTICLE; CALCIUM CURRENT; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; INTRARENAL ARTERY; ISOLATED ARTERY; KIDNEY ARTERY; L TYPE CALCIUM ION CURRENT; MYOGRAPHY; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER;

ACETANILIDES; ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM SIGNALING; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; KIDNEY; MUSCLE, SMOOTH, VASCULAR; MYOGRAPHY; OSMOLAR CONCENTRATION; PATCH-CLAMP TECHNIQUES; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RENAL ARTERY; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84860443563     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.03.010     Document Type: Article

References (22)

1. Allely, M.C., Brown, C.M., Kenny, B.A., Kilpatrick, A.T., Martin, A., Spedding, M., 1993. Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J. Cardiovasc. Pharmacol. 21, 869-873.
2. Antzelevitch, C., Belardinelli, L., Wu, L., Fraser, H., Zygmunt, A.C., Burashnikov, A., Di Diego, J.M., Fish, J.M., Cordeiro, J.M., Goodrow Jr., R.J., Scornik, F., Perez, G., 2004a. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J. Cardiovasc. Pharmacol. Ther. 9 (Suppl. 1), S65-S83.
3. Antzelevitch, C., Belardinelli, L., Zygmunt, A.C., Burashnikov, A., Di Diego, J.M., Fish, J.M., Cordeiro, J.M., Thomas, G., 2004b. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910.
4. Belardinelli, L., Shryock, J.C., Fraser, H., 2006. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 92 (Suppl. 4), iv6-iv14.
5. Chaitman, B.R., 2002. Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor. Curr. Probl. Cardiol. 27, 527-555.
6. Chaitman, B.R., Pepine, C.J., Parker, J.O., Skopal, J., Chumakova, G., Kuch, J., Wang, W., Skettino, S.L., Wolff, A.A., 2004a. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309-316.
7. Chaitman, B.R., Skettino, S.L., Parker, J.O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C.J., Wang, W., Nelson, J.J., Hebert, D.A., Wolff, A.A., 2004b. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43, 1375-1382.
8. Conti, C.R., 2003. Partial fatty acid oxidation (pFOX) inhibition: a new therapy for chronic stable angina. Clin. Cardiol. 26, 161-162.
9. Eckhardt, L.L., Teelin, T.C., January, C.T., 2008. Is ranolazine an antiarrhythmic drug? Am. J. Physiol. Heart Circ. Physiol. 294, H1989-H1991.
10. Letienne, R., Vie, B., Puech, A., Vieu, S., Le Grand, B., John, G.W., 2001. Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the cat cardiovascular system. Naunyn Schmiedebergs Arch. Pharmacol. 363, 464-471.
11. Leung, F.P., Yao, X., Lau, C.W., Ko, W.H., Lu, L., Huang, Y., 2005. Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx. Am. J. Physiol. Renal Physiol. 289, F137-F144.
12. Louis, A.A., Manousos, I.R., Coletta, A.P., Clark, A.L., Cleland, J.G., 2002. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE,MADIT II and REMATCH. Impact of Nicorandil on Angina. Combination Assessment of Ranolazine in Stable Angina. ENhancing Recovery in Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure. Eur. J. Heart Fail. 4, 111-116.
13. Pepine, C.J., Wolff, A.A., 1999. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am. J. Cardiol. 84, 46-50.
14. Sabbah, H.N., Chandler, M.P., Mishima, T., Suzuki, G., Chaudhry, P., Nass, O., Biesiadecki, B.J., Blackburn, B., Wolff, A., Stanley, W.C., 2002. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J. Card. Fail. 8, 416-422.
15. Saint, D.A., 2008. The cardiac persistent sodium current: an appealing therapeutic target? Br. J. Pharmacol. 153, 1133-1142.
16. Scirica, B.M., Morrow, D.A., Hod, H., Murphy, S.A., Belardinelli, L., Hedgepeth, C.M., Molhoek, P., Verheugt, F.W., Gersh, B.J., McCabe, C.H., Braunwald, E., 2007. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116, 1647-1652.
17. Serban, D.N., Nilius, B., Vanhoutte, P.M., 2010. The endothelial saga: the past, the present, the future. Pflugers Arch. 459, 787-792.
18. Song, Y., Shryock, J.C., Wu, L., Belardinelli, L., 2004. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. 44, 192-199.
19. Tsang, S.Y., Yao, X., Essin, K., Wong, C.M., Chan, F.L., Gollasch, M., Huang, Y., 2004. Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels. Stroke 35, 1709-1714.
20. Wu, L., Shryock, J.C., Song, Y., Li, Y., Antzelevitch, C., Belardinelli, L., 2004. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J. Pharmacol. Exp. Ther. 310, 599-605.
21. Yao, Z., Gong, S., Guan, T., Li, Y., Wu, X., Sun, H., 2009. Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities. Chem. Pharm. Bull.(Tokyo) 57, 1218-1222.
22. Zhao, G., Walsh, E., Shryock, J.C., Messina, E., Wu, Y., Zeng, D., Xu, X., Ochoa, M., Baker, S.P., Hintze, T.H., Belardinelli, L., 2011. Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J. Cardiovasc. Pharmacol. 57, 639-647.